TScan Therapeutics, Inc. (TCRX)

TCRX's stock price has experienced a significant decline over the past year, with a 55.96% decrease between January 10, 2025, and January 9, 2026, and a 35.91% decrease over the past six months. Key events impacting the stock price include positive updated data from the AlloHA Phase 1 Heme Trial, a virtual KOL event on AlloHA Phase 1 Trial Data and Market Opportunities, third-quarter 2025 financial results exceeding expectations, participation in the Guggenheim 2nd Annual Healthcare Innovation Conference, a downgrade from Buy to Neutral by BTIG, an agreement with the FDA on the pivotal study design for TSC-101 and strategic prioritization, the appointment of Leiden Dworak as Principal Accounting Officer, and GAAP EPS and revenue exceeding expectations.

Information regarding specific demand seasonality patterns for TScan Therapeutics, Inc.'s products and services is tracked, with data available to identify seasonal trends. However, detailed historical insights into these patterns are not publicly available in the provided search results.

TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T cell receptor-engineered T cell (TCR-T) therapies for cancer treatment. The company's major product candidates include TSC-100 and TSC-101, TCR-T therapy candidates in Phase I clinical trials for hematologic malignancies, and TS-102, which has advanced into IND-enabling activities. Additionally, they are developing multiplexed TCR-T therapy candidates for various solid tumors, including TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.

TScan Therapeutics, Inc. is headquartered in Waltham, Massachusetts, United States. While its core operations are based in the U.S., the company's research partnerships and clinical trial activities extend globally.

TScan Therapeutics' brand reputation has been influenced by positive clinical developments and strategic corporate decisions. Positive data from the AlloHA Phase 1 Heme Trial and promising relapse-free survival data for TSC-101 have boosted confidence. Analyst ratings show a consensus "Hold" with "Buy" recommendations and upside potential. However, strategic prioritization, including pausing enrollment in a solid tumor TCR-T study and a 30% workforce reduction, led to a share drop but is also viewed positively for extending the cash runway.

TScan Therapeutics, Inc. has significant institutional ownership, with 137 institutional owners and shareholders holding a total of 37,314,090 shares. Major institutional owners include Lynx1 Capital Management LP, Bvf Inc/il, Baker Bros. Advisors Lp, BlackRock, Inc., Vanguard Group Inc, Propel Bio Management, LLC, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Standard Life Aberdeen plc, Deer Management Co. LLC, Alphabet Inc., JPMorgan Chase & Co., and Adage Capital Management, L.P. Institutions hold 82.83% of the stock, and insiders have bought more company stock than they have sold in the past three months.